Literature DB >> 30407147

Functional and Morphological Characteristics of Pancreatic Islet Lesions Induced by Quinolone Antimicrobial Agent Gatifloxacin in Rats.

Koichi Yabe1, Yuka Yamamoto2, Takami Suzuki3, Sanae Takada3, Kazuhiko Mori3.   

Abstract

We characterized pancreatic islet lesions induced by several quinolones using functional and morphological examinations of the pancreatic islets in male rats orally administered gatifloxacin, lomefloxacin, or levofloxacin at 300 mg/kg for 14 consecutive days. Consequently, in contrast to lomefloxacin or levofloxacin, gatifloxacin increased serum glucose and glycosylated albumin on day 14 and elevated serum glucose tended to decrease insulin in the intravenous glucose tolerance test. Microscopically, only gatifloxacin induced cytoplasmic vacuoles containing eosinophilic homogenous contents in islet cells. Immunohistochemical examination revealed that vacuolated islet cells were positively stained for insulin, demonstrating they were pancreatic β cells. Electron microscopy showed that the cytoplasmic vacuoles represented dilated cisterna of the rough endoplasmic reticulum filled with electron-lucent materials in pancreatic β cells. Moreover, insulin secretory granules were drastically decreased in vacuolated islet cells, suggesting impaired insulin synthesis and/or transport. This gatifloxacin-induced pancreatic toxicity in rats was considered to be associated with high pancreatic drug distribution. These results demonstrated that gatifloxacin provoked functional and morphological pancreatic β cell alteration associated with impaired insulin synthesis and/or transport, leading to hyperglycemia.

Entities:  

Keywords:  antibacterial agent; drug disposition; hyperglycemia; pancreatic β cell; quinolone; rats

Mesh:

Substances:

Year:  2018        PMID: 30407147     DOI: 10.1177/0192623318809062

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  1 in total

1.  Insulinotropic Potential of Moxifloxacin and Gemifloxacin: An In Vivo Rabbits Model Study Followed by Randomized Phase I Clinical Trial.

Authors:  Abid Ullah; Shujaat Ahmad; Niaz Ali; Shafiq Ur Rahman; Haya Hussain; Saad Alghamdi; Mazen Almehmadi; Anas S Dablool; Azzah M Bannunah; Syeda Hajira Bukhari; Feras Almarshad
Journal:  Antibiotics (Basel)       Date:  2022-01-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.